Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRVI 
Maravai Lifesciences Holdings Inc (MRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MRVI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.12
1 Year Target Price $4.12
| 5 | Strong Buy |
| 1 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.44% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 852.89M USD | Price to earnings Ratio - | 1Y Target Price 4.12 |
Price to earnings Ratio - | 1Y Target Price 4.12 | ||
Volume (30-day avg) 13 | Beta 0.28 | 52 Weeks Range 1.67 - 9.60 | Updated Date 08/29/2025 |
52 Weeks Range 1.67 - 9.60 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.07 | Actual -0.08 |
Profitability
Profit Margin -87.57% | Operating Margin (TTM) -75.3% |
Management Effectiveness
Return on Assets (TTM) -5.89% | Return on Equity (TTM) -54.84% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 438015099 | Price to Sales(TTM) 3.88 |
Enterprise Value 438015099 | Price to Sales(TTM) 3.88 | ||
Enterprise Value to Revenue 1.99 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 144678000 | Shares Floating 92644412 |
Shares Outstanding 144678000 | Shares Floating 92644412 | ||
Percent Insiders 10.16 | Percent Institutions 90.15 |
Upturn AI SWOT
Maravai Lifesciences Holdings Inc
Company Overview
History and Background
Maravai Lifesciences Holdings, Inc. was founded in 2014. It has grown through strategic acquisitions and organic growth, focusing on providing critical products to enable drug development programs.
Core Business Areas
- Nucleic Acid Production: Provides nucleic acid products, including mRNA, DNA, and RNA oligonucleotides used in research, diagnostics, and therapeutics. Includes CleanCap technology.
- Biologics Safety Testing: Offers services and products to ensure the safety and purity of biologics, including antibody production and cell line development services.
Leadership and Structure
Trey Martin serves as the Chief Executive Officer. The company has a typical corporate structure with a board of directors and various functional departments.
Top Products and Market Share
Key Offerings
- CleanCapu00ae: A mRNA capping technology used in vaccine and therapeutic development. Market share is significant in the mRNA production space, potentially >30% although precise figures are difficult to obtain. Competitors include TriLink BioTechnologies (acquired by Danaher), Aldevron, and Thermo Fisher Scientific.
- GMP Nucleic Acids: GMP-grade nucleic acids for use in clinical trials and commercial manufacturing. Market share is estimated at approximately 20%. Key competitors are Thermo Fisher Scientific, Danaher, and Lonza.
- Biologics Safety Testing Services: Testing and analytical services for biologics manufacturers. Market share is relatively fragmented; Maravai's market share likely is around 10-15%. Competitors include Charles River Laboratories, Eurofins Scientific, and WuXi AppTec.
Market Dynamics
Industry Overview
The life sciences industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and biologics. mRNA therapeutics and vaccines are a major driver.
Positioning
Maravai is positioned as a key supplier of critical reagents and services for drug development, particularly in the mRNA space. Its CleanCap technology provides a competitive advantage.
Total Addressable Market (TAM)
The TAM for nucleic acid therapeutics and biologics safety testing is estimated to be tens of billions of dollars. Maravai is well-positioned to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Proprietary technologies like CleanCap
- Strong relationships with pharmaceutical and biotech companies
- Scalable manufacturing capacity
- Established brand reputation
- High-quality products and services
Weaknesses
- Dependence on mRNA market growth
- Customer concentration
- Potential for new competitors entering the market
- High valuation relative to peers
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions to broaden product portfolio
- Increased demand for mRNA therapeutics and vaccines
- Geographic expansion
- Development of innovative technologies
Threats
- Competition from larger life sciences companies
- Changes in regulatory landscape
- Economic downturn impacting research and development spending
- Patent disputes
- Decline in COVID-19 vaccine demand
Competitors and Market Share
Key Competitors
- TMO
- DHR
- LNZGY
Competitive Landscape
Maravai has a strong position in the mRNA space due to its CleanCap technology. However, it faces competition from larger, more diversified life sciences companies.
Major Acquisitions
TriLink BioTechnologies
- Year: 2016
- Acquisition Price (USD millions): 0
- Strategic Rationale: Expanded Maravai's capabilities in custom nucleic acid synthesis.
Growth Trajectory and Initiatives
Historical Growth: Maravai has experienced significant revenue growth in recent years, driven by demand for its products and services in the mRNA space.
Future Projections: Analysts project continued revenue growth for Maravai, although at a slower pace than in recent years.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Maravai Lifesciences Holdingsu00a0Inc.
Summary
Maravai Lifesciences is a key player in the mRNA therapeutics and biologics safety testing markets. The company's proprietary technologies provide a competitive advantage. However, its dependence on the mRNA market and competition from larger players pose challenges. Future growth depends on strategic initiatives and innovation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maravai Lifesciences Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-20 | CEO & Director Mr. Bernd Brust | ||
Sector Healthcare | Industry Biotechnology | Full time employees 560 | Website https://www.maravai.com |
Full time employees 560 | Website https://www.maravai.com | ||
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.